search
Back to results

Real-time Symptom Monitoring Using ePROs to Prevent Adverse Events During Care Transitions

Primary Purpose

Multiple Chronic Conditions, Adverse Event

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
ePRO Application
Sponsored by
Brigham and Women's Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Multiple Chronic Conditions focused on measuring Digital Health, Patient Reported Outcomes, Symptom Monitoring, Predictive Model, Care Transitions, Post Acute Care

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Adult (18 years or older)
  • Hospitalized on the general medicine services at Brigham and Women's Hospital or Brigham and Women's Faulkner Hospital for at least 24 hours
  • Have a discharge status of home, home with services, or facility
  • English-speaking patients or their English-speaking legally designated healthcare proxy or next of kin (i.e., a family caregiver)
  • Non-English-speaking patients who have an English-speaking legally designated healthcare proxy or next of kin (i.e., a family caregiver)
  • Two or more chronic conditions: Anxiety, Asthma*, Arthritis (Osteoarthritis, Rheumatoid), Atrial Fibrillation, Cancer*, Cerebral vascular accident, Chronic kidney disease*, Chronic obstructive pulmonary disease (COPD)*, Cirrhosis, Coronary artery disease/Ischemic heart disease, Dementia, Depression, Diabetes mellitus*, End-stage renal disease*, Heart failure*, Hepatitis B, C*, HIV/AIDs, Hyperlipidemia, Hypertension, Inflammatory bowel disease, Osteoporosis, Sickle cell disease, Substance abuse (Alcohol/Opioid)

Exclusion Criteria:

  • Less than 18 years of age
  • Less than two chronic conditions
  • Hospitalized less than 24 hours
  • No identifiable healthcare proxy or next of kin (i.e., a family caregiver)

Sites / Locations

  • Brigham and Women's Faulkner HospitalRecruiting
  • Brigham and Women's HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

No Intervention

No Intervention

Experimental

Arm Label

Usual Care (Arm 1)

Usual Care (Arm 2)

Intervention (Arm 3)

Arm Description

During the 18-month Baseline Period (Arm 1, n=450) patients will be enrolled and receive usual care to develop the initial predictive model.

During the 30-month Main Trial (RCT) Period, patients will be randomized to usual care (Arm 2, n=425). Data collection for post-discharge AE determination will occur during both periods.

During the 30-month Main Trial (RCT) Period, patients will be randomized to the intervention (Arm 3, n=425). Data collection for post-discharge AE determination will occur during both periods.

Outcomes

Primary Outcome Measures

Actual adverse events (AEs)
The number of actual AEs during the 30-day post-discharge period
Actual preventable adverse events (AEs)
The number of actual AEs during the 30-day post-discharge period

Secondary Outcome Measures

Potential adverse events (AEs)
The number of new or worsening symptoms reported by the patient
Post-discharge healthcare utilization events (hospital readmissions)
Hospital readmissions
Post-discharge healthcare utilization (ambulatory events)
Composite of unanticipated ambulatory, urgent care, ED visits

Full Information

First Posted
February 11, 2022
Last Updated
March 7, 2022
Sponsor
Brigham and Women's Hospital
Collaborators
RAND
search

1. Study Identification

Unique Protocol Identification Number
NCT05282654
Brief Title
Real-time Symptom Monitoring Using ePROs to Prevent Adverse Events During Care Transitions
Official Title
Real-time Symptom Monitoring Using ePROs to Prevent Adverse Events During Care Transitions
Study Type
Interventional

2. Study Status

Record Verification Date
March 2022
Overall Recruitment Status
Recruiting
Study Start Date
February 1, 2022 (Actual)
Primary Completion Date
September 15, 2026 (Anticipated)
Study Completion Date
October 15, 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Brigham and Women's Hospital
Collaborators
RAND

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
This study aims to predict and minimize post-discharge adverse events (AEs) during care transitions through early identification and escalation of patient-reported symptoms to inpatient and ambulatory clinicians by way of predictive algorithms and clinically integrated digital health apps. We will (1) develop and prospectively validate a predictive model of post-discharge AEs for patients with multiple chronic conditions (MCC); (2) combine, adapt, extend, and iteratively refine our EHR-integrated digital health infrastructure in a series of design sessions with patient and clinician participants; (3) conduct a RCT to evaluate the impact of ePRO monitoring on post-discharge AEs for MCC patients discharged from the general medicine service across Brigham Health; and (4) use mixed methods to evaluate barriers and facilitators of implementation and use as we develop a plan for sustainability, scale, and dissemination.
Detailed Description
Adverse events (AE) during care transitions range from 19-28% and may lead to readmissions, representing an ongoing threat to patient safety. Early identification and escalation of patient-reported symptoms to inpatient and ambulatory clinicians is critical, especially for patients with multiple chronic conditions (MCC). Clinically integrated digital health apps have the potential to more accurately predict post-discharge AEs and improve communication for patients, their caregivers, and the care team. Such tools can provide individualized risk assessments of AEs by systematically collecting relevant patient-reported outcomes (PROs) and leveraging standardized application programming interfaces (API) to combine them with electronic health record (EHR) data. While patient-reported outcomes (PROs) are increasingly used in ambulatory settings, their use for real-time symptom monitoring and escalation during transitions from the hospital is novel and potentially transformative-by both empowering patients to better understand their individualized risks of post-discharge AEs, and improving monitoring while transitioning out of the hospital. Our proposed intervention is grounded in evidence-based frameworks for care transitions, and scaling and spread of digital health tools. To inform our intervention, we propose developing and validating a predictive model of post-discharge AEs for 450 MCC patients using relevant PRO questionnaires and electronic health record (EHR) derived variables during our baseline pre-implementation period. Simultaneously, we will combine, adapt, extend, and refine our previously developed EHR-integrated hospital and ambulatory-focused digital health infrastructure to support MCC patients in real-time symptom monitoring using PROs when transitioning out of the hospital. Our intervention uses interoperable, data exchange standards and APIs to seamlessly integrate with existing vendor patient portal offerings, thereby addressing critical gaps and supporting the complete continuum of care. Our multidisciplinary team uses principles of user-centered design and agile software development to rapidly identify, design, develop, refine, and implement requirements from patients and clinicians. Our team will rigorously evaluate this intervention in a large-scale randomized controlled trial of 850 in which we compare our real-time symptom monitoring intervention (425) to usual care (425) for patients with MCCs transitioning out of the hospital. Finally, we will conduct a robust mixed methods evaluation to generate new knowledge and best practices for disseminating, implementing, and using this interoperable intervention at similar institutions with different EHR vendors

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Multiple Chronic Conditions, Adverse Event
Keywords
Digital Health, Patient Reported Outcomes, Symptom Monitoring, Predictive Model, Care Transitions, Post Acute Care

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Baseline, pre-implementation period (usual care arm 1) and main trial (RCT) period (usual care arm 2 and intervention/experimental arm 3)
Masking
InvestigatorOutcomes Assessor
Masking Description
During main trial (post-implementation period), study investigators, outcomes assessor will be masked to randomization status of all participants
Allocation
Randomized
Enrollment
1300 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Usual Care (Arm 1)
Arm Type
No Intervention
Arm Description
During the 18-month Baseline Period (Arm 1, n=450) patients will be enrolled and receive usual care to develop the initial predictive model.
Arm Title
Usual Care (Arm 2)
Arm Type
No Intervention
Arm Description
During the 30-month Main Trial (RCT) Period, patients will be randomized to usual care (Arm 2, n=425). Data collection for post-discharge AE determination will occur during both periods.
Arm Title
Intervention (Arm 3)
Arm Type
Experimental
Arm Description
During the 30-month Main Trial (RCT) Period, patients will be randomized to the intervention (Arm 3, n=425). Data collection for post-discharge AE determination will occur during both periods.
Intervention Type
Behavioral
Intervention Name(s)
ePRO Application
Intervention Description
The intervention consists of a patient portal, EHR-integrated web-app to communicate risk of post-discharge adverse events using patient-reported outcome questionnaires, discharge preparation checklist during hospitalization. After discharge, the intervention will provide real-time symptom monitoring using ePROs and facilitate communication with clinicians based on prediction model-informed ePRO score trends exceeding escalation thresholds.
Primary Outcome Measure Information:
Title
Actual adverse events (AEs)
Description
The number of actual AEs during the 30-day post-discharge period
Time Frame
Up to 30-days after discharge from index hospitalization
Title
Actual preventable adverse events (AEs)
Description
The number of actual AEs during the 30-day post-discharge period
Time Frame
Up to 30-days after discharge from index hospitalization
Secondary Outcome Measure Information:
Title
Potential adverse events (AEs)
Description
The number of new or worsening symptoms reported by the patient
Time Frame
Up to 30-days after discharge from index hospitalization
Title
Post-discharge healthcare utilization events (hospital readmissions)
Description
Hospital readmissions
Time Frame
Up to 30-days after discharge from index hospitalization
Title
Post-discharge healthcare utilization (ambulatory events)
Description
Composite of unanticipated ambulatory, urgent care, ED visits
Time Frame
Up to 30-days after discharge from index hospitalization

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Adult (18 years or older) Hospitalized on the general medicine services at Brigham and Women's Hospital or Brigham and Women's Faulkner Hospital for at least 24 hours Have a discharge status of home, home with services, or facility English-speaking patients or their English-speaking legally designated healthcare proxy or next of kin (i.e., a family caregiver) Non-English-speaking patients who have an English-speaking legally designated healthcare proxy or next of kin (i.e., a family caregiver) Two or more chronic conditions: Anxiety, Asthma*, Arthritis (Osteoarthritis, Rheumatoid), Atrial Fibrillation, Cancer*, Cerebral vascular accident, Chronic kidney disease*, Chronic obstructive pulmonary disease (COPD)*, Cirrhosis, Coronary artery disease/Ischemic heart disease, Dementia, Depression, Diabetes mellitus*, End-stage renal disease*, Heart failure*, Hepatitis B, C*, HIV/AIDs, Hyperlipidemia, Hypertension, Inflammatory bowel disease, Osteoporosis, Sickle cell disease, Substance abuse (Alcohol/Opioid) Exclusion Criteria: Less than 18 years of age Less than two chronic conditions Hospitalized less than 24 hours No identifiable healthcare proxy or next of kin (i.e., a family caregiver)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Anuj Dalal, MD
Phone
(617) 525-8891
Email
adalal1@bwh.harvard.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Savanna Plombon, MPH
Phone
857-307-2668
Email
splombon@bwh.harvard.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Anuj Dalal, MD
Organizational Affiliation
Brigham and Women's Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Brigham and Women's Faulkner Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02115
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Anuj K Dalal, MD
Facility Name
Brigham and Women's Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02115
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Anuj K Dalal, MD

12. IPD Sharing Statement

Learn more about this trial

Real-time Symptom Monitoring Using ePROs to Prevent Adverse Events During Care Transitions

We'll reach out to this number within 24 hrs